JP2024502231A5 - - Google Patents
Info
- Publication number
- JP2024502231A5 JP2024502231A5 JP2023536951A JP2023536951A JP2024502231A5 JP 2024502231 A5 JP2024502231 A5 JP 2024502231A5 JP 2023536951 A JP2023536951 A JP 2023536951A JP 2023536951 A JP2023536951 A JP 2023536951A JP 2024502231 A5 JP2024502231 A5 JP 2024502231A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound according
- pharmaceutical composition
- hydrogen atom
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127341P | 2020-12-18 | 2020-12-18 | |
| US63/127,341 | 2020-12-18 | ||
| PCT/EP2021/086101 WO2022129283A1 (en) | 2020-12-18 | 2021-12-16 | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502231A JP2024502231A (ja) | 2024-01-18 |
| JP2024502231A5 true JP2024502231A5 (enExample) | 2024-12-20 |
Family
ID=79025144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536951A Ceased JP2024502231A (ja) | 2020-12-18 | 2021-12-16 | Ｎａｖ１．８電位依存性ナトリウムチャネルを阻害するためおよびＮａｖ１．８介在疾患を治療するために有用な化学化合物 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4262978A1 (enExample) |
| JP (1) | JP2024502231A (enExample) |
| KR (1) | KR20230121827A (enExample) |
| CN (1) | CN116710463A (enExample) |
| AU (1) | AU2021403606B2 (enExample) |
| CA (1) | CA3202328A1 (enExample) |
| CL (1) | CL2023001750A1 (enExample) |
| CO (1) | CO2023008049A2 (enExample) |
| IL (1) | IL303795A (enExample) |
| MX (1) | MX2023007244A (enExample) |
| PH (1) | PH12023551406A1 (enExample) |
| SA (1) | SA523441263B1 (enExample) |
| WO (1) | WO2022129283A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201604477SA (en) * | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| GB201322602D0 (en) * | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| KR102714561B1 (ko) * | 2017-05-16 | 2024-10-10 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭 |
| MA56398A (fr) * | 2019-06-27 | 2022-05-04 | Glaxosmithkline Ip Dev Ltd | Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 |
-
2021
- 2021-12-16 MX MX2023007244A patent/MX2023007244A/es unknown
- 2021-12-16 WO PCT/EP2021/086101 patent/WO2022129283A1/en not_active Ceased
- 2021-12-16 KR KR1020237023878A patent/KR20230121827A/ko active Pending
- 2021-12-16 IL IL303795A patent/IL303795A/en unknown
- 2021-12-16 CA CA3202328A patent/CA3202328A1/en active Pending
- 2021-12-16 JP JP2023536951A patent/JP2024502231A/ja not_active Ceased
- 2021-12-16 PH PH1/2023/551406A patent/PH12023551406A1/en unknown
- 2021-12-16 EP EP21831047.2A patent/EP4262978A1/en not_active Withdrawn
- 2021-12-16 AU AU2021403606A patent/AU2021403606B2/en active Active
- 2021-12-16 CN CN202180085151.XA patent/CN116710463A/zh active Pending
-
2023
- 2023-06-15 CL CL2023001750A patent/CL2023001750A1/es unknown
- 2023-06-18 SA SA523441263A patent/SA523441263B1/ar unknown
- 2023-06-21 CO CONC2023/0008049A patent/CO2023008049A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6063072B2 (ja) | 水溶性アセトアミノフェン類似体 | |
| JP2020111602A (ja) | 抗がんおよび抗増殖活性を示すｎ−アシル−ｎ’−（ピリジン−２−イル）尿素および類似体 | |
| JP2003519154A5 (enExample) | ||
| JP2021532124A5 (enExample) | ||
| JP2019510787A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| BR112018005194B1 (pt) | Processo para preparar um composto antifúngico | |
| CN103214484A (zh) | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 | |
| CN103781766A (zh) | 用作鞘氨醇-1磷酸酯受体调节剂的取代的双环甲胺衍生物 | |
| BR112016020937B1 (pt) | Processo de preparação de compostos antifúngicos | |
| EP3119748A1 (en) | Antifungal compound process | |
| JP2023515073A5 (enExample) | ||
| JP2024517765A5 (enExample) | ||
| JP2021511305A (ja) | ホスホロ（ン）アミダートアセタールおよびホスファ（ホナ）ートアルセタール化合物 | |
| KR101760970B1 (ko) | 신규의 ep4 아고니스트 | |
| JP2005526832A (ja) | α−ケトアルカン酸エステルまたは−アミドおよび乳酸または乳酸塩を含有する医薬組成物 | |
| JP2008524210A5 (enExample) | ||
| JP2021510168A5 (enExample) | ||
| CA2819597A1 (en) | Oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators | |
| JP2019529472A5 (enExample) | ||
| JP2023546742A (ja) | Ｌｐａ受容体活性に付随する症状を治療するための化合物および組成物 | |
| CN103370102A (zh) | 作为鞘氨醇1-磷酸(s1p)受体调节的新型肟衍生物 | |
| JP2024543111A (ja) | 胃がんの治療に使用するための化合物 | |
| ES2515415T3 (es) | Derivados de 3-(4-((1H-imidazol-1-il)metil)fenil)-5-aril-1,2,4-oxadiazol como moduladores de receptores de la esfingosina-1-fosfato | |
| JP2021530440A5 (enExample) |